![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Pharmacokinetics of simeprevir (TMC435) in volunteers with moderate or severe hepatic impairment
|
|
|
Reported by Jules Levin
EASL 2013 April 24-28 Amsterdam
Sivi Ouwerkerk-Mahadevan,1 Alexandru Simion,2 Kurt Spittaels,2 Maria Beumont-Mauviel2
1Janssen Research and Development, Beerse, Belgium; 2Janssen Infectious Diseases BVBA, Beerse, Belgium
![EASL1.gif](../images/060713/EASL/EASL1.gif)
![EASL2.gif](../images/060713/EASL/EASL2.gif)
![EASL3.gif](../images/060713/EASL/EASL3.gif)
![EASL4.gif](../images/060713/EASL/EASL4.gif)
![EASL5.gif](../images/060713/EASL/EASL5.gif)
![EASL6.gif](../images/060713/EASL/EASL6.gif)
![EASL7.gif](../images/060713/EASL/EASL7.gif)
![EASL8.gif](../images/060713/EASL/EASL8.gif)
![EASL9.gif](../images/060713/EASL/EASL9.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|